T he main abnormality of the uveal tract in patients with Sturge-Weber syndrome is diffuse choroidal hemangioma (DCH). Diffuse choroidal hemangioma can lead to a total retinal detachment and secondary neovascular glaucoma. Radiotherapy and photodynamic therapy are currently the preferred methods of treatment. Low-dose lens-sparing radiotherapy or proton beam irradiation can induce tumor regression and resolution of subretinal fluid.
1 Short-term treatment success using photodynamic therapy has also been reported. 2 The use of oral propranolol hydrochloride has been described for infantile orbital 3 and periorbital hemangioma. Recently, Léauté-Labrèze et al 3 observed that systemic propranolol could inhibit the growth of infantile hemangioma (IH) lesions in children. The response of IH to propranolol catapulted the use of this treatment to first-line status among physicians managing this disease. [3] [4] [5] [6] We report the use of oral propranolol for exudative retinal detachment in DCH associated with SturgeWeber syndrome.
Report of a Case.
A 58-year-old Hispanic woman had decreased visual acuity in the left eye for 3 years and in- An Nd:YAG-laser iridotomy was performed in the left eye, and treatment with oral propranolol hydrochloride (80 mg orally twice a day) was started. At 18 days after the initiation of propranolol treatment, the dosage was reduced to 40 mg twice a day because of secondary effects described by the patient as dizziness and weakness. Six weeks after the initiation of propranolol treatment, best-corrected visual acuity was hand movements OS, intraocular pressure was 21 mm Hg OS, and the retina was attached, with complete reabsorption of subretinal fluid (Figure 2A and B) confirmed by optical coherence tomography ( Figure 2C ) and ultrasonography ( Figure 2D ).
Comment. Propranolol, a nonselective ␤-blocker, was serendipitously discovered to induce accelerated involution of a proliferating IH. 3 The mechanism by which propranolol causes this dramatic effect is unclear. However, propranolol interferes with endothelial cells, vascular tone, angiogenesis, and apoptosis. 5 Léauté-Labrèze and colleagues suggested a propranolol hydrochloride dosage of 2 mg/kg/d in children with IH. We treated our patient with a dosage usually used in adults for arterial hypertension. However, we reduced the dosage by half at day 18 because of secondary effects. Nevertheless, this lower dosage was still effective to allow for resolution of the exudative retinal detachment associated with DCH. The optimal dosage in adults for this indication is still unknown. It is possible that lower dosages may be effective and without adverse effects. In addition, the duration of treatment to induce retinal reattachment is currently unknown. However, patients with IH have been treated for several months. Hemangiomas consist histologically of cavernous and capillary vascular networks. The mechanism by which oral propranolol aids in the resolution of exudative retinal detachment in DCH associated with Sturge-Weber syndrome is unknown. It is possible that, similar to IH, there is vasoconstriction of the DCH due to decreased release of nitric oxide, blocking of proangiogenic signals including vascular endothelial growth factor and basic fibroblast growth factor, and apoptosis in proliferating endothelial cells with vascular tumor regression.
Oguchi Disease With Unusual Findings Associated With a Heterozygous Mutation in the SAG Gene
O guchi disease is a type of congenital stationary night blindness with an autosomal recessive inheritance pattern. Two causative genes have been reported for Oguchi disease: the SAG and GRK1 genes. Homozygous Oguchi disease is characterized by a golden-yellow discoloration of the fundus that disappears after prolonged dark adaptation, called the MizuoNakamura phenomenon. The International Society for Clinical Electrophysiology of Vision-protocol brightflash electroretinograms (ERGs), performed after 30 minutes of dark adaptation, are typically electronegative with a severely reduced b-wave and milder reduction of the a-wave.
1,2 After 3 to 4 hours of dark adaptation, both amplitudes recover to nearly normal, especially the awave. 2 However, the recovered rod function is rapidly lost after a short light exposure or a single bright white flash. 2, 3 We describe a case of Oguchi disease with unusual findings caused by a putative heterozygous mutation in the SAG gene.
Report of a Case.
A 40-year-old woman with visual acuity of 20/20 OU had fundus abnormalities and was referred to our institute. She had photophobia but did not report night blindness. There was no autosomal dominant family history. The retina had a golden-yellow appearance (Figure, A) . The Mizuo-Nakamura phenomenon was observed after 30 minutes of dark adaptation (Figure, B) . Sequencing of the SAG gene identified a heterozygous mutation of 1147del A at codon 309. No mutation was found in GRK1.
The International Society for Clinical Electrophysiology of Vision protocol was used to record the ERGs. Comment. To our knowledge, this is the first case of Oguchi disease with a distinct fundus appearance and mild electrophysiological abnormalities associated with a putative heterozygous SAG mutation. However, we cannot exclude the possibility that another mutation exists in the intron of another allele, which causes the mild phenotype in this patient.
The repetitive-flash ERG protocol was crucial for the diagnosis. It has been reported that double-or tripleflash stimulations after prolonged dark adaption induce ERG alterations in typical patients with Oguchi disease. 3 However, the use of a 30-second interval allowed us to follow the degree of rod function recovery. 
